50 Big Debates in Gynecologic Oncology

Description:

Highlighting over 50 hot topics where controversy exist in management of patients with gynecologic malignancy, this book presents expertly argued opinions for and against, incorporating current evidence and clinical trials outcomes. A diverse range of topics are included that pertain to several disciplines in gynecologic oncology, including surgical management of disease, medical oncology, immunotherapy, radiation therapy, as well as screening, preventive and palliative care. This book will be relevant to a diverse audience of practitioners and trainees including gynecologists, gynecological oncologists, surgeons, medical oncologists, radiation oncologists, and general medics. It will be a useful guide for practicing clinicians managing their patients, as well as a concise textbook for trainees and students preparing for examinations and board certifications in gynecologic oncology. Readers will gain an insight into topical controversies, critically evaluating the different sides to enhance their own clinical practice.

Table of Contents:

Section I: Perioperative Management

1A. Should Routine Mechanical Bowel Preparation be Performed before Primary Debulking Surgery?: Yes

1B. Should Routine Mechanical Bowel Preparation be Performed before Primary Debulking Surgery?: No

2A. Should Preoperative Carbohydrate Loading be Routine prior to Debulking Surgery?: Yes

2B. Should Preoperative Carbohydrate Loading be Routine prior to Debulking Surgery?: No

Section II: Screening, Prevention, and Early Diagnosis

3A. Should Women with BRCA Mutations be Offered Bilateral Salpingectomy with Delayed Oophorectomy fo

Chapter 3B. Should Women with BRCA Mutations be Offered Bilateral Salpingectomy with Delayed Oophore

4A. Can High-risk HPV Testing be Used Alone as the Primary Screening Modality for Cervical Cancer?:

4B. Can High-risk HPV Testing be Used Alone as the Primary Screening Modality for Cervical Cancer?:

Section III: Ovarian Cancer

5A. Should CA-125 Surveillance be Performed after Completion of Primary Treatment for Ovarian Cancer

5B. Should CA-125 Surveillance be Performed after Completion of Primary Treatment for Ovarian Cancer

6A. In Patients with BRCA-negative and HRD-negative Epithelial Ovarian Cancer, Should Molecular Prof

6B. In Patients with BRCA-negative and HRD-negative Epithelial Ovarian Cancer, Should Molecular Prof

7A. Is MEK Inhibitor Therapy the Best Treatment Recommendation for Low-Grade Serous Ovarian Cancer P

7B. Is MEK Inhibitor Therapy the Best Treatment Recommendation for Low-Grade Serous Ovarian Cancer P

8A. Should Stage IC Mucinous Ovarian Carcinoma be Managed by Observation or Adjuvant Chemotherapy?:

8B. Should Stage IC Mucinous Ovarian Carcinoma be Managed by Observation or Adjuvant Chemotherapy?:

9A. How Many Cycles of Adjuvant Chemotherapy Should be Administered to Patients with High-risk Stage

9B. How Many Cycles of Adjuvant Chemotherapy Should be Administered to Patients with High-risk Stage

10A. Patients with Advanced Ovarian Cancer who are 75 Years Old and Above Should Routinely be Treate

10B. Patients with Advanced Ovarian Cancer who are 75 Years Old and Above Should Routinely be Treate

11A. Should an Attempt at Aggressive Cytoreduction be Made for all Surgical Candidates with Advanced

11B. Should an Attempt at Aggressive Cytoreduction be Made for all Surgical Candidates with Advanced

12A. Should Minimally Invasive Modalities be Routinely/Uniformly Utilized for Assessment of Resectab

12B. Should Laparoscopic Modalities be Routinely Utilized for Assessment of Resectability prior to A

13A. Should Enlarged Supradiaphragmatic Lymph Nodes be Routinely Removed during Debulking Surgery Pr

13B. Should Enlarged Supradiaphragmatic Lymph Nodes be Routinely Removed during Debulking Surgery Pr

14A. Is there a Role for Hyperthermic Intraperitoneal Chemotherapy in Front-line Therapy for Ovarian

14B. Is there a Role for Hyperthermic Intraperitoneal Chemotherapy in Front-line Therapy for Ovarian

15A. Is there a Role for Intraperitoneal Chemotherapy after Optimal Cytoreduction of Ovarian Cancer?

15B. Is there a Role for Intraperitoneal Chemotherapy after Optimal Cytoreduction of Ovarian Cancer?

16A. What is the Best Front-line Maintenance Therapy for HRD-positive Ovarian Cancer?: Single-agent

16B. What is the Best Front-line Maintenance Therapy for HRD-positive Ovarian Cancer?: Bevacizumab p

17A. When is the Best Time to Use PARP Inhibitors for Maintenance?: Front-line

17B. When is the Best Time to Use PARP Inhibitors for Maintenance?: First Recurrence

18A. What is the best front-line maintenance therapy for optimally debulked HRD-negative advanced ep

18B. What is the best front-line maintenance therapy for optimally debulked HRD-negative advanced ep

19A. What is the Optimal Therapeutic Option for Platinum-resistant Recurrent Ovarian Cancer: Single-

19B. What is the Optimal Therapeutic Option for Platinum-resistant Recurrent Ovarian Cancer?: Other

20A. Should Patients with Platinum-sensitive Recurrent Ovarian Cancer Undergo Secondary Cytoreductio

20B. Should All Patients with Platinum-sensitive Recurrent Ovarian Cancer be Considered for Secondar

21A. Should Tertiary Debulking for Patients with Recurrent Ovarian Cancer be Performed?: Yes

21B. Should Tertiary Debulking be Performed for Patients with Recurrent Ovarian Cancer?: No

22A. Is there a Role for Immunotherapy in Ovarian Cancer?: Yes

22B. Is there a Role for Immunotherapy in Ovarian Cancer?: Not Yet

23A. What is the Best Management Option for Malignant Bowel Obstruction?: Surgery

23B. What is the Best Management Option for Malignant Bowel Obstruction?: Percutaneous Endoscopic Ga

24A. What is the Optimal Chemotherapy Regimen for Ovarian Germ-cell Tumors?: Bleomycin, Etoposide, a

24B. What is the Optimal Chemotherapy Regimen for Ovarian Germ-cell Tumors?: Other

25A. What is the Optimal Adjuvant Chemotherapy Regimen for Primary Granulosa Cell Tumor?: Bleomycin,

25B. What is the Optimal Adjuvant Chemotherapy Regimen for Primary Granulosa Cell Tumor?: Carboplati

26A. What is the Best Management Strategy for a Recurrent Granulosa Cell Tumor?: Surgery

26B. What is the Best Management Strategy for Recurrent Granulosa Cell Tumor?: Chemotherapy

27A. Is progression-free survival a rational surrogate endpoint in front-line ovarian cancer clinica

27B. Is progression-free survival a rational surrogate endpoint in front-line ovarian cancer clinica

Section IV: Endometrial Cancer

28A. Fertility-sparing Surgery in Early-stage Endometrial Cancer is Safe and Does not Compromise Onc

28B. Fertility-sparing Treatment for Early-stage Endometrial Cancer is Safe and Does Not Compromise

29A. Sentinel Lymph Node Mapping Should be the Standard for Staging Patients with High-grade Endomet

29B. Sentinel Lymph Node Mapping Should be the Standard for Staging Patients with High-grade Endomet

30A. Molecular Profiling Should be Done to Guide the Management of Endometrial Cancer?: Yes

30B. Molecular Profiling Should be Done to Guide the Management of Endometrial Cancer?: No

31A. What is the Best Adjuvant Therapy for Management of Stage III Endometrial Cancer?: Chemotherapy

31B. What is the Best Adjuvant Therapy for Management of Stage III Endometrial Cancer?: Combined Che

32A. How Should Stage IA Serous Papillary Endometrial Cancer Confined to a Polyp or the Endometrial

32B. How Should Stage IA Serous Papillary Endometrial Cancer Confined to a Polyp or the Endometrial

33A. What is the Optimal Sequence of Therapy for Patients with Stage IIIC Endometrial Carcinoma Trea

33B. What is the Optimal Sequence of Therapy for Patients with Stage IIIC Endometrial Carcinoma Trea

34A. Should an Attempt at Debulking Grossly Metastatic Endometrial Cancer be Undertaken?: Yes

34B. Should an Attempt at Debulking Grossly Metastatic Endometrial Cancer be Undertaken?: No

35A. Should Secondary Cytoreduction be Performed for Recurrent Endometrial Cancer?: Sometimes

35B. Should Secondary Cytoreduction be Performed for Recurrent Endometrial Cancer?: Never

36A. Is Hormonal Therapy the Best Therapy for Chemo-resistant Endometrial Cancer?: Yes

36B. Is Hormonal Therapy the Best Therapy for Chemo-resistant Endometrial Cancer?: No

37A. Is there a Role for Using Immunotherapy in Endometrial Cancer?: Yes

37B. Is there a Role for Using Immunotherapy in Endometrial Cancer?: No

38A. What is the Best Chemotherapy Regimen for Uterine Carcinosarcoma?: Carboplatin/Paclitaxel

38B. What is the Best Chemotherapy Regimen for Uterine Carcinosarcoma?: The Case for “Other” Reg

39A. What is the Best Management for Premenopausal Women with Early-stage Uterine Leiomyosarcoma Sta

39B. What is the Best Management for Premenopausal Women with Early-stage Uterine Leiomyosarcoma Sta

40A. Should Primary Debulking Surgery be Performed for Metastatic Leiomyosarcoma?: Yes

40B. Should Primary Debulking Surgery be Performed for Metastatic Leiomyosarcoma?: No

41A. Should Secondary Cytoreductive Surgery be Offered to all Patients that are Surgical Candidates

41B. Should Secondary Cytoreductive Surgery be Offered to all Patients that are Surgical Candidates

Section V: Cervical Cancer

42A. Is there a Role for Minimally Invasive Radical Hysterectomy for Management of Cervical Cancer?:

42B. Is there a Role for Minimally Invasive Radical Hysterectomy for Management of Cervical Cancer?:

43A. Is Radical Surgery or Parametrectomy Needed for Early-stage FIGO IA2 and Microscopic IB1 Cervic

43B. Is Radical Surgery or Parametrectomy Needed for Early-stage FIGO IA2 and Microscopic IB1 Cervic

44A. What is the Best Management Option for Young Women with Stage IB2 Cervical Cancer Who Wish to P

44B. What is the Best Management Option for Young Women with Stage IB2 Cervical Cancer Who Wish to P

45A. Should Adjuvant Hysterectomy be Performed for Patients with Locally Advanced Cervical Cancer Tr

45B. Should Adjuvant Hysterectomy be Performed for Patients with Locally Advanced Cervical Cancer Tr

46A. What is the Best Initial Treatment for Stage IB3 to IIB Cervical Cancer?: Neoadjuvant Chemother

46B. What is the Best Initial Treatment for Stage IB3 to IIB Cervical Cancer?: Primary Chemoradiatio

47A. Is there a Role for Immunotherapy in Treatment of Cervical Cancer?: Yes

47B. Is there a Role for Immunotherapy in Treatment of Cervical Cancer?: No

Section VI: Vaginal and Vulvar Cancer

48A. Should the Subsequent Management of Patients with Vulvar Cancer and a Positive Sentinel Lymph N

48B. Should the Subsequent Management of Patients with Vulvar Cancer and a Positive Sentinel Lymph N

49A. What is the Best Treatment for Stage I Vulvar Squamous Cell Carcinoma with either a Close or Po

49B. What is the Best Treatment for Stage I Vulvar Squamous Cell Carcinoma with either a Close or Po

50A Should Adjuvant Radiation be Given to Women with Single Node Positive Vulvar Cancer?: Yes

50B Should Adjuvant Radiation Therapy be Given to Patients with Single Node Positive Vulvar Cancer?:

51A. Is Pelvic Exenteration an Option for a Pelvic Recurrence of a Vulvar/Vaginal Melanoma after Pre

51B. Is Pelvic Exenteration an Option for a Pelvic Recurrence of a Vulvar/Vaginal Melanoma after Pre

Index